Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Maccura and Qiagen Form Next-Gen Sequencing JV in China

publication date: May 5, 2017
China's Maccura Biotechnology formed a joint venture with Qiagen of the Netherlands to develop and market Qiagen's GeneReader NGS system in China. Maccura is a China IVD company. It will own 60% of the JV, which is named Maqgen, while Qiagen will own the rest. Qiagen claims the GeneReader NGS System is the world's first complete Sample-to-Insight reader and makes NGS available to any laboratory. The JV will focus initially on research use of the machine and broaden that to include Class III hospital networks. More details....

Stock Symbols: (SHZ: 300463) (NSDQ: QGEN)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China